Please ensure Javascript is enabled for purposes of website accessibility

Why 3D Systems, Stratasys, and Proto Labs Stocks All Popped Today

By Rich Smith - Jan 27, 2021 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

3D printing human body parts? Yep. That's apparently a thing now.

What happened

On a down day for stock markets, shares of companies involved in the 3D printing business -- additive manufacturing -- are doing just fine. More than fine, actually. As of 1:45 p.m. EST, shares of 3D Systems (DDD -3.46%) had blasted off to a 16.5% gain, while archrival Stratasys (SSYS -1.96%) and 3D prototype manufacturer Proto Labs (PRLB 0.98%) had risen 8.5% and 10.7%, respectively.

So what

What's the reason for the ruckus? "Market volatility" is the easiest answer -- and there's certainly been enough of that happening lately! But in the 3D printing sector in particular, there's also some actual news of note today.

Specifically, 3D Systems -- the stock that's leading the sector higher today -- announced a "breakthrough in bioprinting technology" today, and an "expansion of regenerative medicine." 3D systems cited "tremendous progress made in collaboration with United Therapeutics Corporation (UTHR 1.82%)" in manufacturing human organs for transplant utilizing "3D printing systems for solid-organ scaffolds." Now, the company says it intends to "invest, further develop, and commercialize solutions for the diverse application opportunities in regenerative medicine."  

3D printer printing a human-like head

3D Systems is really "ahead" of the curve in additive manufacturing. Image source: Getty Images.

Now what

That's right, folks. 3D is in the body parts-printing business now. From industrial roots, it's basically evolved into a biotech stock.

Going forward, it's hard to say precisely how this will play out. Even 3D Systems admits that this is only a "nascent industry." It remains to be seen whether a rival like Stratasys can imitate 3D's success -- or what role a prototype like Proto Labs might play. But as for 3D Systems itself, the company says its "Print to Perfusion" process is capable of 3D printing "full size, vascularized, rapid, micron-level scaffolds on which to perfuse living human cells to grow functioning human organs. The company further believes that the ability to grow organs artificially in this manner has "the potential to enable novel laboratory testing methods to accelerate the development of new drug therapies while reducing the need for animal testing."

In a masterful example of understatement, 3D Systems calls its new ability to help grow human organs with a 3D printer "an exciting growth driver for our healthcare business."

It's certainly exciting 3D printing investors today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

3D Systems Corporation Stock Quote
3D Systems Corporation
DDD
$9.77 (-3.46%) $0.35
Stratasys Ltd. Stock Quote
Stratasys Ltd.
SSYS
$18.52 (-1.96%) $0.37
United Therapeutics Corporation Stock Quote
United Therapeutics Corporation
UTHR
$238.29 (1.82%) $4.27
Proto Labs, Inc. Stock Quote
Proto Labs, Inc.
PRLB
$47.60 (0.98%) $0.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.